282 related articles for article (PubMed ID: 36871057)
1. Clinical advances in epigenetic therapies for lymphoma.
Rosenthal AC; Munoz JL; Villasboas JC
Clin Epigenetics; 2023 Mar; 15(1):39. PubMed ID: 36871057
[TBL] [Abstract][Full Text] [Related]
2. Emerging epigenetic-modulating therapies in lymphoma.
Sermer D; Pasqualucci L; Wendel HG; Melnick A; Younes A
Nat Rev Clin Oncol; 2019 Aug; 16(8):494-507. PubMed ID: 30837715
[TBL] [Abstract][Full Text] [Related]
3. Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.
Morschhauser F; Salles G; Batlevi CL; Tilly H; Chaidos A; Phillips T; Burke J; Melnick A
Blood Rev; 2022 Nov; 56():100988. PubMed ID: 35851487
[TBL] [Abstract][Full Text] [Related]
4. Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
Lue JK; Amengual JE; O'Connor OA
Curr Oncol Rep; 2015 Sep; 17(9):40. PubMed ID: 26141799
[TBL] [Abstract][Full Text] [Related]
5. Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.
Hassler MR; Schiefer AI; Egger G
Epigenomics; 2013 Aug; 5(4):397-415. PubMed ID: 23895653
[TBL] [Abstract][Full Text] [Related]
6. Methylation alterations and advance of treatment in lymphoma.
Liu MK; Sun XJ; Gao XD; Qian Y; Wang L; Zhao WL
Front Biosci (Landmark Ed); 2021 Sep; 26(9):602-613. PubMed ID: 34590470
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.
Cani AK; Soliman M; Hovelson DH; Liu CJ; McDaniel AS; Haller MJ; Bratley JV; Rahrig SE; Li Q; Briceño CA; Tomlins SA; Rao RC
Mod Pathol; 2016 Jul; 29(7):685-97. PubMed ID: 27102345
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
11. Targeting epigenetic regulators in the treatment of T-cell lymphoma.
Ahmed N; Feldman AL
Expert Rev Hematol; 2020 Feb; 13(2):127-139. PubMed ID: 31903826
[No Abstract] [Full Text] [Related]
12. Clinical efficiency of epigenetic drugs therapy in bone malignancies.
de Nigris F; Ruosi C; Napoli C
Bone; 2021 Feb; 143():115605. PubMed ID: 32829036
[TBL] [Abstract][Full Text] [Related]
13. The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review.
Rugo HS; Jacobs I; Sharma S; Scappaticci F; Paul TA; Jensen-Pergakes K; Malouf GG
Adv Ther; 2020 Jul; 37(7):3059-3082. PubMed ID: 32445185
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
Katarzyna R; Lucyna B
J Cancer Res Ther; 2019; 15(5):961-970. PubMed ID: 31603095
[TBL] [Abstract][Full Text] [Related]
15. Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.
Gelato KA; Adler D; Ocker M; Haendler B
Expert Opin Ther Targets; 2016 Jul; 20(7):783-99. PubMed ID: 26799480
[TBL] [Abstract][Full Text] [Related]
16. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance.
Guo L; Lee YT; Zhou Y; Huang Y
Semin Cancer Biol; 2022 Aug; 83():487-502. PubMed ID: 33421619
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics and B-cell lymphoma.
Shaknovich R; Melnick A
Curr Opin Hematol; 2011 Jul; 18(4):293-9. PubMed ID: 21577103
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Options for Aggressive T-Cell Lymphomas.
Lue JK; Kress A; Amengual JE
Curr Hematol Malig Rep; 2017 Aug; 12(4):269-281. PubMed ID: 28573497
[TBL] [Abstract][Full Text] [Related]
19. Use of histone methyltransferase inhibitors in cancer treatment: A systematic review.
Marzochi LL; Cuzziol CI; Nascimento Filho CHVD; Dos Santos JA; Castanhole-Nunes MMU; Pavarino ÉC; Guerra ENS; Goloni-Bertollo EM
Eur J Pharmacol; 2023 Apr; 944():175590. PubMed ID: 36775112
[TBL] [Abstract][Full Text] [Related]
20. Exploiting epigenetic dependencies in ovarian cancer therapy.
Coughlan AY; Testa G
Int J Cancer; 2021 Nov; 149(10):1732-1743. PubMed ID: 34213777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
